INCY News and Press, Incyte Corporation From 01/29/21

Incyte ([[INCY]] -1.9%) announces that the European Medicines Agency's ((EMA)) Committee for Medicinal Products for Human Use ((CHMP)) has issued a positive recommendation for its marketing application of pemigatinib for the treatment of certain adults with a form of unresectable locally adva...

- If approved, pemigatinib will be the first targeted therapy indicated in the EU for this indication Incyte (Nasdaq:INCY) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommend...

Incyte (INCY) announces that the FDA has accepted for Priority Review its Biologics License Application for retifanlimab, an intravenous PD-1 inhibitor, as a potential treatment for adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal ((SCAC)) who have ...

Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review its Biologics License Application (BLA) for retifanlimab, an intravenous PD-1 inhibitor, as a potential treatment for adult patients with locally advanced or metastatic...

Incyte (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2020 financial results conference call and webcast for 8:00 a.m. ET on Tuesday, February 9, 2021. The schedule for the press release and conference call/webcast is as follows: If you are u...

Health Canada has accepted for review Incyte (INCY) and MorphoSys' (MOR) marketing application seeking approval for tafasitamab in combination with lenalidomide, followed by tafasitamab monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymp...

Incyte and MorphoSys Announce Acceptance by Health Canada of the New Drug Submission for Tafasitamab Canada NewsWire MONTREAL and PLANEGG/ MUNICH, Germany , Jan. 12, 2021 /CNW/ - Incyte (NASDAQ: INCY) and MorphoSys AG (FSE: MOR; Prime Standard Segment; M...

Strong SACCOVID clinical trial results suggest an approval is forthcoming. Graft versus Host Disease linkage to the most promising therapeutics. Merck business model resonating with investors. Small pool of therapeutic drug companies represents ideal acquisition targets. ...

Incyte Corporation ([[INCY]] +2.6%) and Cellenkos inks a development collaboration to evaluate the combination of Jakafi (ruxolitinib) and CK0804, Cellenkos' cryopreserved CXCR4 enriched, allogeneic, umbilical cord blood-derived T-regulatory cells, in patients with myelofibrosis, MF.Addi...

- Incyte and Cellenkos will evaluate the combination of ruxolitinib (Jakafi ® ) and CK0804, cord blood-derived T-regulatory cells, in patients with myelofibrosis - Incyte has an exclusive option to acquire sole rights to CK0804 Incyte (Nasdaq:INCY) and Celle...